Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Select Medical Holdings Corporation Announces Results For Its Third Quarter Ended September 30, 2021 and Cash Dividend


      News provided by

      Select Medical Holdings Corporation

      Nov 04, 2021, 16:30 ET

      Share this article

      Share this article


      MECHANICSBURG, Pa., Nov. 4, 2021 /PRNewswire/ -- Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") (NYSE: SEM) today announced results for its third quarter ended September 30, 2021 and the declaration of a cash dividend.

      For the third quarter ended September 30, 2021, revenue increased 7.8% to $1,534.2 million, compared to $1,423.9 million for the same quarter, prior year. Income from operations was $150.3 million for the third quarter ended September 30, 2021, compared to $156.1 million for the same quarter, prior year. Income from operations included $1.7 million of other operating income related to the recognition of payments received under the Provider Relief Fund for the third quarter ended September 30, 2021, compared to a reduction of other operating income of $1.2 million related to payments received under the Provider Relief Fund for the same quarter, prior year. Refer to "CARES Act Provider Relief Fund" for further discussion. Net income was $100.2 million for the third quarter ended September 30, 2021, compared to $104.5 million for the same quarter, prior year. Net income included pre-tax gains on sales of businesses of $5.1 million for the third quarter ended September 30, 2020. Adjusted EBITDA was $208.6 million for the third quarter ended September 30, 2021, compared to $213.2 million for the same quarter, prior year. Earnings per common share was $0.57 for both the third quarters ended September 30, 2021 and 2020. Adjusted earnings per common share was $0.57 for the third quarter ended September 30, 2021, compared to $0.56 for the same quarter, prior year. Adjusted earnings per common share excluded the gains on sales of businesses and related tax effects for the third quarter ended September 30, 2020. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table IX of this release. A reconciliation of earnings per common share to adjusted earnings per common share is presented in table X of this release.

      For the nine months ended September 30, 2021, revenue increased 14.1% to $4,644.7 million, compared to $4,071.2 million for the same period, prior year. Income from operations increased 57.4% to $636.2 million for the nine months ended September 30, 2021, compared to $404.3 million for the same period, prior year. Income from operations included $115.8 million of other operating income related to the recognition of payments received under the Provider Relief Fund for the nine months ended September 30, 2021, compared to $53.8 million for the same period, prior year. Refer to "CARES Act Provider Relief Fund" for further discussion. Net income increased 78.9% to $433.6 million for the nine months ended September 30, 2021, compared to $242.4 million for the same period, prior year. Net income included pre-tax gains on sales of businesses of $12.7 million for the nine months ended September 30, 2020. Adjusted EBITDA increased 39.6% to $808.9 million for the nine months ended September 30, 2021, compared to $579.3 million for the same period, prior year. Earnings per common share increased to $2.61 for the nine months ended September 30, 2021, compared to $1.35 for the same period, prior year. Adjusted earnings per common share was $2.61 for the nine months ended September 30, 2021, compared to $1.31 for the same period, prior year. Adjusted earnings per common share excluded the gains on sales of businesses and related tax effects for the nine months ended September 30, 2020. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table IX of this release. A reconciliation of earnings per common share to adjusted earnings per common share is presented in table X of this release.

      Please refer to "Effects of the COVID-19 Pandemic on Select Medical's Results of Operations" below for further discussion regarding the impact of the coronavirus disease 2019 ("COVID-19") pandemic on Select Medical's operating results.

      Company Overview

      Select Medical is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States based on number of facilities.   Select Medical's reportable segments include the critical illness recovery hospital segment, the rehabilitation hospital segment, the outpatient rehabilitation segment, and the Concentra segment. As of September 30, 2021, Select Medical operated 100 critical illness recovery hospitals in 28 states, 30 rehabilitation hospitals in 12 states, and 1,850 outpatient rehabilitation clinics in 39 states and the District of Columbia. Select Medical's joint venture subsidiary Concentra operated 519 occupational health centers in 41 states. At September 30, 2021, Select Medical had operations in 46 states and the District of Columbia. Information about Select Medical is available at www.selectmedical.com.

      CARES Act Provider Relief Fund

      On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was enacted. The CARES Act provided additional waivers, reimbursement, grants and other funds to assist health care providers during the COVID-19 pandemic, including appropriations for the Public Health and Social Services Emergency Fund, also referred to as the Provider Relief Fund, to be used for preventing, preparing, and responding to COVID-19, and for reimbursing eligible health care providers for health care related expenses and lost revenues that are attributable to COVID-19.

      For the three and nine months ended September 30, 2021, Select Medical recognized $1.7 million and $115.8 million of payments received under the Provider Relief Fund as other operating income, respectively.

      For the three months ended September 30, 2020, Select Medical recognized a reduction to other operating income of $1.2 million related to payments received under the Provider Relief Fund. This resulted from changes in the terms and conditions associated with the Provider Relief Fund program. For the nine months ended September 30, 2020, Select Medical recognized $53.8 million of payments received under the Provider Relief Fund as other operating income.

      Critical Illness Recovery Hospital Segment

      For the third quarter ended September 30, 2021, revenue for the critical illness recovery hospital segment increased 2.2% to $530.6 million, compared to $519.5 million for the same quarter, prior year. Adjusted EBITDA for the critical illness recovery hospital segment was $57.2 million for the third quarter ended September 30, 2021, compared to $88.8 million for the same quarter, prior year. The Adjusted EBITDA margin for the critical illness recovery hospital segment was 10.8% for the third quarter ended September 30, 2021, compared to 17.1% for the same quarter, prior year. Certain critical illness recovery hospital key statistics are presented in table VII of this release for both the third quarters ended September 30, 2021 and 2020.

      For the nine months ended September 30, 2021, revenue for the critical illness recovery hospital segment increased 8.4% to $1,669.6 million, compared to $1,539.6 million for the same period, prior year. Adjusted EBITDA for the critical illness recovery hospital segment was $243.4 million for the nine months ended September 30, 2021, compared to $267.1 million for the same period, prior year. For the nine months ended September 30, 2021, Adjusted EBITDA included $17.9 million of other operating income related to the outcome of litigation with the Centers for Medicare & Medicaid Services. The Adjusted EBITDA margin for the critical illness recovery hospital segment was 14.6% for the nine months ended September 30, 2021, compared to 17.4% for the same period, prior year. Certain critical illness recovery hospital key statistics are presented in table VIII of this release for both the nine months ended September 30, 2021 and 2020.

      Rehabilitation Hospital Segment

      For the third quarter ended September 30, 2021, revenue for the rehabilitation hospital segment increased 13.0% to $212.4 million, compared to $188.1 million for the same quarter, prior year. Adjusted EBITDA for the rehabilitation hospital segment was $44.1 million for the third quarter ended September 30, 2021, compared to $44.6 million for the same quarter, prior year. The Adjusted EBITDA margin for the rehabilitation hospital segment was 20.7% for the third quarter ended September 30, 2021, compared to 23.7% for the same quarter, prior year. Certain rehabilitation hospital key statistics are presented in table VII of this release for both the third quarters ended September 30, 2021 and 2020.

      For the nine months ended September 30, 2021, revenue for the rehabilitation hospital segment increased 17.5% to $632.9 million, compared to $538.8 million for the same period, prior year. Adjusted EBITDA for the rehabilitation hospital segment increased 31.2% to $145.4 million for the nine months ended September 30, 2021, compared to $110.8 million for the same period, prior year. The Adjusted EBITDA margin for the rehabilitation hospital segment was 23.0% for the nine months ended September 30, 2021, compared to 20.6% for the same period, prior year. Certain rehabilitation hospital key statistics are presented in table VIII of this release for both the nine months ended September 30, 2021 and 2020.

      Outpatient Rehabilitation Segment

      For the third quarter ended September 30, 2021, revenue for the outpatient rehabilitation segment increased 14.4% to $274.5 million, compared to $240.0 million for the same quarter, prior year. Adjusted EBITDA for the outpatient rehabilitation segment increased 26.6% to $38.8 million for the third quarter ended September 30, 2021, compared to $30.6 million for the same quarter, prior year. The Adjusted EBITDA margin for the outpatient rehabilitation segment was 14.1% for the third quarter ended September 30, 2021, compared to 12.8% for the same quarter, prior year. Certain outpatient rehabilitation key statistics are presented in table VII of this release for both the third quarters ended September 30, 2021 and 2020.

      For the nine months ended September 30, 2021, revenue for the outpatient rehabilitation segment increased 21.8% to $806.9 million, compared to $662.4 million for the same period, prior year. Adjusted EBITDA for the outpatient rehabilitation segment increased to $110.7 million for the nine months ended September 30, 2021, compared to $51.5 million for the same period, prior year. The Adjusted EBITDA margin for the outpatient rehabilitation segment was 13.7% for the nine months ended September 30, 2021, compared to 7.8%  for the same period, prior year. Certain outpatient rehabilitation key statistics are presented in table VIII of this release for both the nine months ended September 30, 2021 and 2020.

      Concentra Segment

      For the third quarter ended September 30, 2021, revenue for the Concentra segment increased 12.8% to $442.2 million, compared to $391.9 million for the same quarter, prior year. Adjusted EBITDA for the Concentra segment increased 23.9% to $99.8 million for the third quarter ended September 30, 2021, compared to $80.5 million for the same quarter, prior year. Adjusted EBITDA included other operating income of $1.6 million related to the recognition of payments received under the Provider Relief Fund for the third quarter ended September 30, 2021, compared to $0.4 million for the same quarter, prior year. The Adjusted EBITDA margin for the Concentra segment was 22.6% for the third quarter ended September 30, 2021, compared to 20.6% for the same quarter, prior year. Certain Concentra key statistics are presented in table VII of this release for both the third quarters ended September 30, 2021 and 2020.

      For the nine months ended September 30, 2021, revenue for the Concentra segment increased 19.8% to $1,321.4 million, compared to $1,102.7 million for the same period, prior year. Adjusted EBITDA for the Concentra segment increased to $318.9 million for the nine months ended September 30, 2021, compared to $183.5 million for the same period, prior year. Adjusted EBITDA included other operating income of $33.8 million related to the recognition of payments received under the Provider Relief Fund for the nine months ended September 30, 2021, compared to $1.1 million for the same period, prior year. The Adjusted EBITDA margin for the Concentra segment was 24.1% for the nine months ended September 30, 2021, compared to 16.6% for the same period, prior year. Certain Concentra key statistics are presented in table VIII of this release for both the nine months ended September 30, 2021 and 2020.

      Effects of the COVID-19 Pandemic on Select Medical's Results of Operations

      Beginning in March 2020, state governments placed significant restrictions on businesses and mandated closures of non-essential or non-life sustaining businesses, causing many employers to furlough their workforce and temporarily cease or significantly reduce their operations. State governments also implemented restrictions on travel and individual activities outside of the home, closed schools, and mandated other social distancing measures. At the same time, hospitals and other facilities began suspending elective surgeries. In an effort to ensure hospitals and health systems had the capacity to absorb and effectively manage surges of COVID-19 patients, a number of waivers and modifications of certain requirements under the Medicare, Medicaid and Children's Health Insurance Program ("CHIP") programs were authorized in March 2020, including certain regulations under the Medicare program which govern admissions into Select Medical's critical illness recovery hospitals and rehabilitation hospitals. Specifically, Select Medical's critical illness recovery hospitals which are certified as long-term care hospitals ("LTCHs") became exempt from the greater-than-25-day average length of stay requirement for all cost reporting periods that include the COVID-19 public health emergency period. Select Medical's rehabilitation hospitals which are certified as inpatient rehabilitation facilities ("IRFs") could exclude patients admitted solely to respond to the emergency from the calculation of the "60 percent rule" thresholds to receive payment as an IRF. The COVID-19 public health emergency period has been extended and is currently in effect through January 15, 2022.

      The adverse effects of the COVID-19 pandemic, along with the actions of governmental authorities and those in the private sector to limit the spread of COVID-19, caused disruptions in each of Select Medical's segments; these disruptions were most significant within the outpatient rehabilitation and Concentra segments. By mid-March 2020, Select Medical's outpatient rehabilitation clinics began experiencing significantly less patient visit volume due to declines in patient referrals from physicians, a reduction in workers' compensation injury visits resulting from the temporary closure of businesses, and the suspension of elective surgeries which would have required outpatient rehabilitation services. Select Medical's Concentra centers experienced similar declines in patient visit volume due to businesses furloughing their workforce and temporarily ceasing or significantly reducing their operations. Since March 2021, Select Medical's outpatient rehabilitation clinics and Concentra centers have experienced patient visit volumes which approximate or exceed the levels experienced in the months prior to the widespread emergence of COVID-19 in the United States. Although they have experienced temporary disruptions in their core businesses as a result of the COVID-19 pandemic, Select Medical's outpatient rehabilitation and Concentra segments have been able to expand their services to provide COVID-19 screening and testing.

      Select Medical's critical illness recovery hospitals have played a critical role in caring for patients during the COVID-19 pandemic, and the relaxation of certain admission restrictions have contributed to volume increases in certain of its hospitals. The revenue of Select Medical's critical illness recovery hospitals and rehabilitation hospitals has also benefited from the temporary suspension of the 2.0% cut to Medicare payments due to sequestration, which began May 1, 2020 following the enactment of the CARES Act, and has been extended through December 31, 2021. Certain of Select Medical's rehabilitation hospitals experienced temporary declines in patient volume, beginning in March 2020, in areas more significantly impacted by the spread of COVID-19, and as a result of the suspension of elective surgeries at hospitals and other facilities, which consequently reduced the demand for inpatient rehabilitation services. Additionally, some of Select Medical's rehabilitation hospitals temporarily restricted admissions as a result of the COVID-19 pandemic. Beginning at the onset of the COVID-19 pandemic, both Select Medical's critical illness recovery hospitals and rehabilitation hospitals modified certain of their protocols in order to follow the guidelines and recommendations for patient treatment and for the protection of their patients and staff members. This has resulted in increased labor costs, including increased contracted labor usage, as well as additional costs resulting from the purchase of personal protective equipment.

      The unpredictable effects of the COVID-19 pandemic, including the duration and extent of disruption on Select Medical's operations, creates uncertainties about Select Medical's future operating results and financial condition. Select Medical has provided revenue and certain operating statistics below for each of its segments for each of the periods presented. Please refer to our risk factors previously reported in our Annual Report on Form 10-K for the year ended December 31, 2020 for further discussion.



      Critical Illness Recovery Hospital































      Revenue



      Patient Days



      Occupancy Rate



      Number of Hospitals
      Owned(1)



      2019


      2020


      2021



      2019


      2020


      2021



      2019


      2020


      2021



      2019


      2020


      2021



      (in thousands)






















      January


      $

      149,799



      $

      163,238



      $

      199,611




      86,238



      90,783



      100,933




      69%


      69%


      75%



      96


      100


      99

      February


      145,586



      165,375



      190,703




      80,806



      87,844



      92,036




      71%


      72%


      75%



      96


      100


      99

      March


      162,149



      171,908



      204,558




      91,085



      91,831



      100,149




      73%


      70%


      74%



      96


      100


      99

      Three Months Ended March 31


      $

      457,534



      $

      500,521



      $

      594,872




      258,129



      270,458



      293,118




      71%


      70%


      75%



      96


      100


      99





























      April


      $

      156,231



      $

      171,445



      $

      185,934




      88,357



      90,710



      91,506




      70%


      71%


      70%



      99


      100


      99

      May


      156,422



      178,223



      183,471




      89,350



      95,191



      93,708




      69%


      72%


      70%



      99


      100


      99

      June


      148,490



      169,958



      174,654




      85,153



      90,988



      87,767




      68%


      71%


      68%



      99


      100


      99

      Three Months Ended June 30


      $

      461,143



      $

      519,626



      $

      544,059




      262,860



      276,889



      272,981




      69%


      72%


      69%



      99


      100


      99

      Six Months Ended June 30


      $

      918,677



      $

      1,020,147



      $

      1,138,931




      520,989



      547,347



      566,099




      70%


      71%


      72%



      99


      100


      99





























      July


      $

      151,416



      $

      175,253



      $

      171,483




      87,143



      94,144



      88,119




      67%


      71%


      65%



      99


      99


      100

      August


      155,485



      173,967



      178,240




      86,553



      93,964



      91,756




      66%


      71%


      68%



      99


      99


      100

      September


      155,991



      170,234



      180,923




      84,393



      90,955



      92,579




      67%


      71%


      71%



      99


      99


      100

      Three Months Ended
      September 30


      $

      462,892



      $

      519,454



      $

      530,646




      258,089



      279,063



      272,454




      67%


      71%


      68%



      99


      99


      100

      Nine Months Ended
      September 30


      $

      1,381,569



      $

      1,539,601



      $

      1,669,577




      779,078



      826,410



      838,553




      69%


      71%


      70%



      99


      99


      100



      Rehabilitation Hospital































      Revenue



      Patient Days



      Occupancy Rate



      Number of Hospitals
      Owned(1)



      2019


      2020


      2021



      2019


      2020


      2021



      2019


      2020


      2021



      2019


      2020


      2021



      (in thousands)





















      January


      $

      50,615



      $

      61,673



      $

      68,297




      27,434



      32,111



      34,404




      74%


      79%


      82%



      17


      19


      20

      February


      48,080



      60,690



      64,202




      25,442



      31,813



      32,178




      76%


      84%


      84%



      17


      19


      20

      March


      55,863



      59,656



      75,305




      29,940



      30,644



      35,857




      78%


      76%


      85%



      18


      19


      20

      Three Months Ended March 31


      $

      154,558



      $

      182,019



      $

      207,804




      82,816



      94,568



      102,439




      76%


      79%


      84%



      18


      19


      20





























      April


      $

      51,991



      $

      45,878



      $

      70,295




      28,266



      23,553



      34,861




      76%


      61%


      85%



      18


      19


      20

      May


      56,019



      57,815



      71,190




      29,730



      29,787



      35,604




      75%


      73%


      84%



      19


      19


      20

      June


      52,364



      64,974



      71,181




      28,529



      30,741



      34,483




      73%


      78%


      84%



      19


      19


      20

      Three Months Ended June 30


      $

      160,374



      $

      168,667



      $

      212,666




      86,525



      84,081



      104,948




      75%


      71%


      85%



      19


      19


      20

      Six Months Ended June 30


      $

      314,932



      $

      350,686



      $

      420,470




      169,341



      178,649



      207,387




      76%


      75%


      84%



      19


      19


      20





























      July


      $

      57,077



      $

      62,312



      $

      70,467




      30,054



      31,986



      34,894




      75%


      81%


      83%



      19


      18


      20

      August


      58,072



      63,673



      71,682




      30,228



      32,518



      34,835




      75%


      83%


      83%



      19


      18


      20

      September


      58,220



      62,090



      70,285




      29,172



      31,176



      33,224




      75%


      82%


      81%



      19


      18


      20

      Three Months Ended
      September 30


      $

      173,369



      $

      188,075



      $

      212,434




      89,454



      95,680



      102,953




      75%


      82%


      82%



      19


      18


      20

      Nine Months Ended
      September 30


      $

      488,301



      $

      538,761



      $

      632,904




      258,795



      274,329



      310,340




      75%


      77%


      84%



      19


      18


      20



      Outpatient Rehabilitation
























      Revenue



      Visits



      Working Days(2)



      2019


      2020


      2021



      2019


      2020


      2021



      2019


      2020


      2021



      (in thousands)














      January


      $

      83,185



      $

      90,924



      $

      76,763




      687,007



      757,171



      625,964




      22



      22



      20


      February


      78,573



      88,239



      77,063




      658,610



      739,061



      641,942




      20



      20



      20


      March


      85,147



      76,086



      98,135




      708,866



      626,433



      832,248




      21



      22



      23


      Three Months Ended March 31


      $

      246,905



      $

      255,249



      $

      251,961




      2,054,483



      2,122,665



      2,100,154




      63



      64



      63























      April


      $

      90,230



      $

      49,084



      $

      95,251




      762,914



      386,108



      810,314




      22



      22



      22


      May


      90,272



      51,186



      89,030




      759,829



      409,703



      758,773




      22



      20



      20


      June


      81,389



      66,868



      96,128




      680,762



      546,456



      835,774




      20



      22



      22


      Three Months Ended June 30


      $

      261,891



      $

      167,138



      $

      280,409




      2,203,505



      1,342,267



      2,404,861




      64



      64



      64


      Six Months Ended June 30


      $

      508,796



      $

      422,387



      $

      532,370




      4,257,988



      3,464,932



      4,505,015




      127



      128



      127























      July


      $

      89,267



      $

      77,793



      $

      90,352




      754,102



      636,826



      780,118




      22



      22



      21


      August


      90,687



      79,034



      93,056




      743,813



      651,738



      798,459




      22



      21



      22


      September


      85,376



      83,215



      91,132




      706,413



      694,808



      768,493




      20



      21



      21


      Three Months Ended
      September 30


      $

      265,330



      $

      240,042



      $

      274,540




      2,204,328



      1,983,372



      2,347,070




      64



      64



      64


      Nine Months Ended
      September 30


      $

      774,126



      $

      662,429



      $

      806,910




      6,462,316



      5,448,304



      6,852,085




      191



      192



      191




      Concentra


























      Revenue



      Visits



      Working Days(2)




      2019


      2020


      2021



      2019


      2020


      2021



      2019


      2020


      2021




      (in thousands)















      January


      $

      133,507



      $

      141,236



      $

      127,103




      985,598



      1,032,069



      867,793




      22



      22



      20



      February


      126,309



      133,690



      132,349




      919,065



      965,741



      869,910




      20



      20



      20



      March


      136,505



      123,609



      163,388




      1,006,944



      879,585



      1,057,871




      21



      22



      23



      Three Months Ended March 31


      $

      396,321



      $

      398,535



      $

      422,840




      2,911,607



      2,877,395



      2,795,574




      63



      64



      63

























      April


      $

      140,050



      $

      91,178



      $

      152,143




      1,040,543



      610,555



      999,622




      22



      22



      22



      May


      143,183



      99,228



      142,228




      1,073,763



      674,629



      956,250




      22



      20



      20



      June


      130,218



      121,932



      162,001




      988,783



      865,896



      1,074,206




      20



      22



      22



      Three Months Ended June 30


      $

      413,451



      $

      312,338



      $

      456,372




      3,103,089



      2,151,080



      3,030,078




      64



      64



      64



      Six Months Ended June 30


      $

      809,772



      $

      710,873



      $

      879,212




      6,014,696



      5,028,475



      5,825,652




      127



      128



      127

























      July


      $

      142,385



      $

      132,465



      $

      146,509




      1,057,809



      930,427



      1,033,266




      22



      22



      21



      August


      144,452



      130,291



      150,333




      1,087,165



      933,555



      1,106,356




      22



      21



      22



      September


      135,063



      129,103



      145,348




      1,005,929



      963,065



      1,084,009




      20



      21



      21



      Three Months Ended
      September 30


      $

      421,900



      $

      391,859



      $

      442,190




      3,150,903



      2,827,047



      3,223,631




      64



      64



      64



      Nine Months Ended
      September 30


      $

      1,231,672



      $

      1,102,732



      $

      1,321,402




      9,165,599



      7,855,522



      9,049,283




      191



      192



      191




      ______________________________

      (1)

      Represents the number of hospitals owned at the end of each period presented. 

      (2)

      Represents the number of days in which normal business operations were conducted during the periods presented.

      Stock Repurchase Program

      The board of directors of Select Medical previously authorized a common stock repurchase program to repurchase up to $500.0 million worth of shares of its common stock. On November 2, 2021, the board of directors increased the capacity of the program from $500.0 million to $1.0 billion worth of shares and the program has been extended until December 31, 2023. The common stock repurchase program will remain in effect until then, unless further extended or earlier terminated by the board of directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Select Medical deems appropriate. Select Medical funds this program with cash on hand and borrowings under its revolving credit facility.

      During the quarter ended September 30, 2021, Select Medical repurchased 1,383,508 shares at a cost of approximately $47.5 million, or $34.34 per share, which includes transaction costs.  Since the inception of the common stock repurchase program through September 30, 2021, Select Medical has repurchased 39,964,416 shares at a cost of approximately $404.1 million, or $10.11 per share, which includes transaction costs.

      Dividend

      On November 2, 2021, Select Medical's board of directors declared a cash dividend of $0.125 per share. The dividend will be payable on or about November 29, 2021 to stockholders of record as of the close of business on November 16, 2021.

      There is no assurance that future dividends will be declared. The declaration and payment of dividends in the future are at the discretion of Select Medical's board of directors after taking into account various factors, including, but not limited to, Select Medical's financial condition, operating results, available cash and current and anticipated cash needs, the terms of Select Medical's indebtedness, and other factors Select Medical's board of directors may deem to be relevant.

      Business Outlook

      Select Medical is updating its business outlook for 2021 following the reporting of its third quarter 2021 results. Select Medical now expects revenue for the full year of 2021 to be in the range of $6.05 billion to $6.15 billion and Adjusted EBITDA for the full year of 2021 to be in the range of $980.0 million to $1.0 billion. Select Medical now expects fully diluted earnings per common share for the full year of 2021 to be in the range of $2.98 to $3.09. A reconciliation of net income to Adjusted EBITDA for the full year of 2021 is presented in table XI of this release.

      Select Medical reaffirms its target compound annual growth rates, provided most recently in its August 5, 2021 press release, for revenue, Adjusted EBITDA, and earnings per common share. Select Medical continues to expect its compound annual growth for revenue to be in the range of 4% to 6% and compound annual growth for Adjusted EBITDA to be in the range of 7% to 8% from 2021 through 2023. Select Medical continues to expect compound annual growth for earnings per common share to be in the range of 17% to 20% from 2021 through 2023.

      Conference Call

      Select Medical will host a conference call regarding its third quarter results, as well as its business outlook and the impact of the COVID-19 pandemic on each of its reportable segments, on Friday, November 5, 2021, at 9:00am ET. The domestic dial in number for the call is 1-866-440-2669. The international dial in number is 1-409-220-9844. The conference ID for the call is 2359393. The conference call will be webcast simultaneously and can be accessed at Select Medical Holdings Corporation's website www.selectmedicalholdings.com.

      For those unable to participate in the conference call, a replay will be available until 12:00pm ET, November 12, 2021. The replay number is 1-855-859-2056 (domestic) or 1-404-537-3406 (international). The conference ID for the replay will be 2359393. The replay can also be accessed at Select Medical Holdings Corporation's website, www.selectmedicalholdings.com.

      Certain statements contained herein that are not descriptions of historical facts are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995), including statements related to Select Medical's 2021 and long-term business outlook. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements due to factors including the following:

      • developments related to the COVID-19 pandemic including, but not limited to, the duration and severity of the pandemic, additional measures taken by government authorities and the private sector to limit the spread of COVID-19, and further legislative and regulatory actions which impact healthcare providers, including actions that may impact the Medicare program;
      • changes in government reimbursement for our services and/or new payment policies may result in a reduction in revenue, an increase in costs, and a reduction in profitability;
      • the failure of our Medicare-certified long term care hospitals or inpatient rehabilitation facilities to maintain their Medicare certifications may cause our revenue and profitability to decline;
      • the failure of our Medicare-certified long term care hospitals and inpatient rehabilitation facilities operated as "hospitals within hospitals" to qualify as hospitals separate from their host hospitals may cause our revenue and profitability to decline;
      • a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;
      • acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources or expose us to unforeseen liabilities;
      • our plans and expectations related to our acquisitions and our ability to realize anticipated synergies;
      • private third-party payors for our services may adopt payment policies that could limit our future revenue and profitability;
      • the failure to maintain established relationships with the physicians in the areas we serve could reduce our revenue and profitability;
      • shortages in qualified nurses, therapists, physicians, or other licensed providers, or the inability to attract or retain healthcare professionals due to the heightened risk of infection related to the COVID-19 pandemic, could increase our operating costs significantly or limit our ability to staff our facilities;
      • competition may limit our ability to grow and result in a decrease in our revenue and profitability;
      • the loss of key members of our management team could significantly disrupt our operations;
      • the effect of claims asserted against us could subject us to substantial uninsured liabilities;
      • a security breach of our or our third-party vendors' information technology systems may subject us to potential legal and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 or the Health Information Technology for Economic and Clinical Health Act; and
      • other factors discussed from time to time in our filings with the Securities and Exchange Commission (the "SEC"), including factors discussed under the heading "Risk Factors" of the quarterly reports on Form 10-Q and of the annual report on Form 10-K for the year ended December 31, 2020.

      Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

      Investor inquiries:
      Joel T. Veit
      Senior Vice President and Treasurer
      717-972-1100
      [email protected]

      I.  Condensed Consolidated Statements of Operations

      For the Three Months Ended September 30, 2020 and 2021

      (In thousands, except per share amounts, unaudited)




      2020


      2021


      % Change

      Revenue


      $

      1,423,869



      $

      1,534,221



      7.8

      %

      Costs and expenses:







      Cost of services, exclusive of depreciation and amortization


      1,180,951



      1,297,682



      9.9


      General and administrative


      35,516



      37,885



      6.7


      Depreciation and amortization


      50,110



      50,128



      0.0


      Total costs and expenses


      1,266,577



      1,385,695



      9.4


      Other operating income


      (1,160)



      1,729



      N/M


      Income from operations


      156,132



      150,255



      (3.8)


      Other income and expense:







      Equity in earnings of unconsolidated subsidiaries


      8,765



      11,452



      30.7


      Gain on sale of businesses


      5,143



      —



      N/M


      Interest expense


      (34,026)



      (33,825)



      (0.6)


      Income before income taxes


      136,014



      127,882



      (6.0)


      Income tax expense


      31,557



      27,665



      (12.3)


      Net income


      104,457



      100,217



      (4.1)


      Less: Net income attributable to non-controlling interests


      27,511



      23,289



      (15.3)


      Net income attributable to Select Medical


      $

      76,946



      $

      76,928



      0.0

      %

      Basic and diluted earnings per common share:(1)


      $

      0.57



      $

      0.57





      ______________________________

      (1)

      Refer to table III for calculation of earnings per common share.



      N/M

      Not meaningful.

      II.  Condensed Consolidated Statements of Operations

      For the Nine Months Ended September 30, 2020 and 2021

      (In thousands, except per share amounts, unaudited)




      2020


      2021


      % Change

      Revenue


      $

      4,071,219



      $

      4,644,704



      14.1

      %

      Costs and expenses:







      Cost of services, exclusive of depreciation and amortization


      3,463,778



      3,882,579



      12.1


      General and administrative


      102,808



      109,025



      6.0


      Depreciation and amortization


      154,133



      150,702



      (2.2)


      Total costs and expenses


      3,720,719



      4,142,306



      11.3


      Other operating income


      53,828



      133,837



      N/M


      Income from operations


      404,328



      636,235



      57.4


      Other income and expense:







      Equity in earnings of unconsolidated subsidiaries


      19,677



      33,180



      68.6


      Gain on sale of businesses


      12,690



      —



      N/M


      Interest income


      —



      4,749



      N/M


      Interest expense


      (117,499)



      (102,115)



      (13.1)


      Income before income taxes


      319,196



      572,049



      79.2


      Income tax expense


      76,805



      138,410



      80.2


      Net income


      242,391



      433,639



      78.9


      Less: Net income attributable to non-controlling interests


      60,670



      81,271



      34.0


      Net income attributable to Select Medical


      $

      181,721



      $

      352,368



      93.9

      %

      Basic and diluted earnings per common share:(1)


      $

      1.35



      $

      2.61





      ______________________________

      (1)

      Refer to table III for calculation of earnings per common share.



      N/M

      Not meaningful.

      III.  Earnings per Share

      For the Three and Nine Months Ended September 30, 2020 and 2021

      (In thousands, except per share amounts, unaudited)


      Select Medical's capital structure includes common stock and unvested restricted stock awards. To compute earnings per share ("EPS"), Select Medical applies the two-class method because its unvested restricted stock awards are participating securities which are entitled to participate equally with its common stock in undistributed earnings.


      The following table sets forth the net income attributable to Select Medical, its common shares outstanding, and its participating securities outstanding for the three and nine months ended September 30, 2020 and 2021:




      Basic and Diluted EPS



      Three Months Ended

      September 30,


      Nine Months Ended
      September 30,



      2020


      2021


      2020


      2021



      (in thousands)

      Net income


      $

      104,457



      $

      100,217



      $

      242,391



      $

      433,639


      Less: net income attributable to non-controlling interests


      27,511



      23,289



      60,670



      81,271


      Net income attributable to Select Medical


      76,946



      76,928



      181,721



      352,368


      Less: net income attributable to participating securities


      2,666



      2,550



      6,254



      11,781


      Net income attributable to common shares


      $

      74,280



      $

      74,378



      $

      175,467



      $

      340,587


      The following tables set forth the computation of EPS under the two-class method for the three and nine months ended September 30, 2020 and 2021:




      Three Months Ended September 30,



      2020



      2021



      Net Income
      Allocation


      Shares(1)


      Basic and
      Diluted EPS



      Net Income
      Allocation


      Shares(1)


      Basic and
      Diluted EPS

      Common shares


      $

      74,280



      129,882



      $

      0.57




      $

      74,378



      130,594



      $

      0.57


      Participating securities


      2,666



      4,662



      $

      0.57




      2,550



      4,477



      $

      0.57


      Total


      $

      76,946








      $

      76,928









      Nine Months Ended September 30,



      2020



      2021



      Net Income
      Allocation


      Shares(1)


      Basic and
      Diluted EPS



      Net Income
      Allocation


      Shares(1)


      Basic and
      Diluted EPS

      Common shares


      $

      175,467



      129,616



      $

      1.35




      $

      340,587



      130,441



      $

      2.61


      Participating securities


      6,254



      4,620



      $

      1.35




      11,781



      4,512



      $

      2.61


      Total


      $

      181,721








      $

      352,368







      ______________________________

      (1)

      Represents the weighted average share count outstanding during the period.

      IV.  Condensed Consolidated Balance Sheets

      (In thousands, unaudited)




      December 31, 2020


      September 30, 2021

      Assets





      Current Assets:





      Cash and cash equivalents


      $

      577,061



      $

      747,983


      Accounts receivable


      896,763



      898,823


      Other current assets


      120,176



      132,535


      Total Current Assets


      1,594,000



      1,779,341


      Operating lease right-of-use assets


      1,032,217



      1,069,953


      Property and equipment, net


      943,420



      936,695


      Goodwill


      3,379,014



      3,399,794


      Identifiable intangible assets, net


      387,541



      378,433


      Other assets


      319,207



      335,257


      Total Assets


      $

      7,655,399



      $

      7,899,473


      Liabilities and Equity





      Current Liabilities:





      Payables and accruals


      $

      800,918



      $

      919,976


      Government advances


      321,807



      159,505


      Unearned government assistance


      82,607



      2,414


      Current operating lease liabilities


      220,413



      226,419


      Current portion of long-term debt and notes payable


      12,621



      18,059


      Total Current Liabilities


      1,438,366



      1,326,373


      Non-current operating lease liabilities


      875,367



      909,950


      Long-term debt, net of current portion


      3,389,398



      3,384,164


      Non-current deferred tax liability


      132,421



      120,274


      Other non-current liabilities


      168,703



      167,770


      Total Liabilities


      6,004,255



      5,908,531


      Redeemable non-controlling interests


      398,171



      627,330


      Total equity


      1,252,973



      1,363,612


      Total Liabilities and Equity


      $

      7,655,399



      $

      7,899,473


      V.  Condensed Consolidated Statements of Cash Flows

      For the Three Months Ended September 30, 2020 and 2021

      (In thousands, unaudited)




      2020


      2021

      Operating activities





      Net income


      $

      104,457



      $

      100,217


      Adjustments to reconcile net income to net cash provided by operating activities:





      Distributions from unconsolidated subsidiaries


      10,497



      8,388


      Depreciation and amortization


      50,110



      50,128


      Provision for expected credit losses


      28



      (40)


      Equity in earnings of unconsolidated subsidiaries


      (8,765)



      (11,452)


      Gain on sale of assets and businesses


      (16,842)



      (581)


      Stock compensation expense


      6,962



      8,194


      Amortization of debt discount, premium and issuance costs


      542



      560


      Deferred income taxes


      (11,140)



      (3,642)


      Changes in operating assets and liabilities, net of effects of business combinations:





      Accounts receivable


      (104,592)



      32,396


      Other current assets


      (23,528)



      11,034


      Other assets


      4,831



      8,860


      Accounts payable and accrued expenses


      133,748



      17,795


      Government advances


      1,124



      (91,767)


      Unearned government assistance


      21,433



      (1,684)


      Income taxes


      (34,328)



      (29,452)


      Net cash provided by operating activities


      134,537



      98,954


      Investing activities





      Business combinations, net of cash acquired


      (7,115)



      (16,749)


      Purchases of property and equipment


      (34,319)



      (48,944)


      Investment in businesses


      (11,108)



      (5,182)


      Proceeds from sale of assets and businesses


      70,919



      1,794


      Net cash provided by (used in) investing activities


      18,377



      (69,081)


      Financing activities





      Borrowings of other debt


      3,599



      10,600


      Principal payments on other debt


      (7,087)



      (7,596)


      Dividends paid to common stockholders


      —



      (16,940)


      Repurchase of common stock


      (4,827)



      (64,440)


      Proceeds from issuance of non-controlling interests


      —



      14,238


      Distributions to and purchases of non-controlling interests


      (14,536)



      (21,245)


      Net cash used in financing activities


      (22,851)



      (85,383)


      Net increase (decrease) in cash and cash equivalents


      130,063



      (55,510)


      Cash and cash equivalents at beginning of period


      509,737



      803,493


      Cash and cash equivalents at end of period


      $

      639,800



      $

      747,983


      Supplemental information





      Cash paid for interest


      $

      54,050



      $

      51,615


      Cash paid for taxes


      77,025



      60,763


      VI.  Condensed Consolidated Statements of Cash Flows

      For the Nine Months Ended September 30, 2020 and 2021

      (In thousands, unaudited)




      2020


      2021

      Operating activities





      Net income


      $

      242,391



      $

      433,639


      Adjustments to reconcile net income to net cash provided by operating activities:





      Distributions from unconsolidated subsidiaries


      21,720



      27,772


      Depreciation and amortization


      154,133



      150,702


      Provision for expected credit losses


      281



      172


      Equity in earnings of unconsolidated subsidiaries


      (19,677)



      (33,180)


      Gain on sale of assets and businesses


      (24,723)



      (87)


      Stock compensation expense


      20,828



      22,002


      Amortization of debt discount, premium and issuance costs


      1,635



      1,655


      Deferred income taxes


      (14,556)



      (11,965)


      Changes in operating assets and liabilities, net of effects of business combinations:





      Accounts receivable


      (91,413)



      645


      Other current assets


      (22,815)



      (1,822)


      Other assets


      16,335



      (3,124)


      Accounts payable and accrued expenses


      142,027



      107,710


      Government advances


      318,116



      (165,470)


      Unearned government assistance


      66,938



      (80,193)


      Income taxes


      9,415



      13,524


      Net cash provided by operating activities


      820,635



      461,980


      Investing activities





      Business combinations, net of cash acquired


      (14,076)



      (26,830)


      Purchases of property and equipment


      (105,572)



      (125,386)


      Investment in businesses


      (25,857)



      (16,367)


      Proceeds from sale of assets and businesses


      83,320



      11,257


      Net cash used in investing activities


      (62,185)



      (157,326)


      Financing activities





      Borrowings on revolving facilities


      470,000



      —


      Payments on revolving facilities


      (470,000)



      —


      Payments on term loans


      (39,843)



      —


      Borrowings of other debt


      35,086



      19,515


      Principal payments on other debt


      (42,820)



      (22,910)


      Dividends paid to common stockholders


      —



      (33,816)


      Repurchase of common stock


      (14,242)



      (66,050)


      Proceeds from issuance of non-controlling interests


      1,686



      19,926


      Distributions to and purchases of non-controlling interests


      (28,196)



      (50,397)


      Purchase of membership interests of Concentra Group Holdings Parent


      (366,203)



      —


      Net cash used in financing activities


      (454,532)



      (133,732)


      Net increase in cash and cash equivalents


      303,918



      170,922


      Cash and cash equivalents at beginning of period


      335,882



      577,061


      Cash and cash equivalents at end of period


      $

      639,800



      $

      747,983


      Supplemental information





      Cash paid for interest


      $

      140,174



      $

      118,570


      Cash paid for taxes


      81,945



      136,857


      VII.  Key Statistics

      For the Three Months Ended September 30, 2020 and 2021

      (unaudited)




      2020


      2021


      % Change

      Critical Illness Recovery Hospital







      Number of hospitals – end of period(a)


      100



      100




      Revenue (,000)


      $

      519,454



      $

      530,646



      2.2

      %

      Number of patient days(b)(c)


      279,063



      272,454



      (2.4)

      %

      Number of admissions(b)(d)


      9,380



      9,250



      (1.4)

      %

      Revenue per patient day(b)(e)


      $

      1,845



      $

      1,931



      4.7

      %

      Adjusted EBITDA (,000)


      $

      88,830



      $

      57,245



      (35.6)

      %

      Adjusted EBITDA margin


      17.1

      %


      10.8

      %



      Rehabilitation Hospital







      Number of hospitals – end of period(a)


      29



      30




      Revenue (,000)


      $

      188,075



      $

      212,434



      13.0

      %

      Number of patient days(b)(c)


      95,680



      102,953



      7.6

      %

      Number of admissions(b)(d)


      6,443



      7,243



      12.4

      %

      Revenue per patient day(b)(e)


      $

      1,775



      $

      1,881



      6.0

      %

      Adjusted EBITDA (,000)


      $

      44,637



      $

      44,076



      (1.3)

      %

      Adjusted EBITDA margin


      23.7

      %


      20.7

      %



      Outpatient Rehabilitation







      Number of clinics – end of period(a)


      1,777



      1,850




      Revenue (,000)


      $

      240,042



      $

      274,540



      14.4

      %

      Number of visits(b)(f)


      1,983,372



      2,347,070



      18.3

      %

      Revenue per visit(b)(g)


      $

      104



      $

      102



      (1.9)

      %

      Adjusted EBITDA (,000)


      $

      30,623



      $

      38,762



      26.6

      %

      Adjusted EBITDA margin


      12.8

      %


      14.1

      %



      Concentra







      Number of centers – end of period(b)


      523



      519




      Revenue (,000)


      $

      391,859



      $

      442,190



      12.8

      %

      Number of visits(b)(f)


      2,827,047



      3,223,631



      14.0

      %

      Revenue per visit(b)(g)


      $

      121



      $

      124



      2.5

      %

      Adjusted EBITDA (,000)


      $

      80,547



      $

      99,832



      23.9

      %

      Adjusted EBITDA margin


      20.6

      %


      22.6

      %




      ______________________________

      (a)

      Includes managed locations.

      (b)

      Excludes managed locations. For purposes of the Concentra segment, onsite clinics and community-based outpatient clinics are excluded.

      (c)

      Each patient day represents one patient occupying one bed for one day during the periods presented.

      (d)

      Represents the number of patients admitted to Select Medical's hospitals during the periods presented.

      (e)

      Represents the average amount of revenue recognized for each patient day. Revenue per patient day is calculated by dividing patient service revenues, excluding revenues from certain other ancillary and outpatient services provided at Select Medical's hospitals, by the total number of patient days.

      (f)

      Represents the number of visits in which patients were treated at Select Medical's outpatient rehabilitation clinics and Concentra centers during the periods presented.

      (g)

      Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated by dividing patient service revenue, excluding revenues from certain other ancillary services, by the total number of visits. For purposes of this computation for the Concentra segment, patient service revenue does not include onsite clinics and community-based outpatient clinics.

      VIII.  Key Statistics

      For the Nine Months Ended September 30, 2020 and 2021

      (unaudited)




      2020


      2021


      % Change

      Critical Illness Recovery Hospital







      Number of hospitals – end of period(a)


      100



      100




      Revenue (,000)


      $

      1,539,601



      $

      1,669,577



      8.4

      %

      Number of patient days(b)(c)


      826,410



      838,553



      1.5

      %

      Number of admissions(b)(d)


      28,080



      28,135



      0.2

      %

      Revenue per patient day(b)(e)


      $

      1,850



      $

      1,982



      7.1

      %

      Adjusted EBITDA (,000)


      $

      267,143



      $

      243,421



      (8.9)

      %

      Adjusted EBITDA margin


      17.4

      %


      14.6

      %



      Rehabilitation Hospital







      Number of hospitals – end of period(a)


      29



      30




      Revenue (,000)


      $

      538,761



      $

      632,904



      17.5

      %

      Number of patient days(b)(c)


      274,329



      310,340



      13.1

      %

      Number of admissions(b)(d)


      18,489



      21,734



      17.6

      %

      Revenue per patient day(b)(e)


      $

      1,777



      $

      1,861



      4.7

      %

      Adjusted EBITDA (,000)


      $

      110,811



      $

      145,378



      31.2

      %

      Adjusted EBITDA margin


      20.6

      %


      23.0

      %



      Outpatient Rehabilitation







      Number of clinics – end of period(a)


      1,777



      1,850




      Revenue (,000)


      $

      662,429



      $

      806,910



      21.8

      %

      Number of visits(b)(f)


      5,448,304



      6,852,085



      25.8

      %

      Revenue per visit(b)(g)


      $

      105



      $

      103



      (1.9)

      %

      Adjusted EBITDA (,000)


      $

      51,463



      $

      110,724



      115.2

      %

      Adjusted EBITDA margin


      7.8

      %


      13.7

      %



      Concentra







      Number of centers – end of period(b)


      523



      519




      Revenue (,000)


      $

      1,102,732



      $

      1,321,402



      19.8

      %

      Number of visits(b)(f)


      7,855,522



      9,049,283



      15.2

      %

      Revenue per visit(b)(g)


      $

      123



      $

      125



      1.6

      %

      Adjusted EBITDA (,000)


      $

      183,510



      $

      318,907



      73.8

      %

      Adjusted EBITDA margin


      16.6

      %


      24.1

      %




      ______________________________

      (a)

      Includes managed locations.

      (b)

      Excludes managed locations. For purposes of the Concentra segment, onsite clinics and community-based outpatient clinics are excluded.

      (c)

      Each patient day represents one patient occupying one bed for one day during the periods presented.

      (d)

      Represents the number of patients admitted to Select Medical's hospitals during the periods presented.

      (e)

      Represents the average amount of revenue recognized for each patient day. Revenue per patient day is calculated by dividing patient service revenues, excluding revenues from certain other ancillary and outpatient services provided at Select Medical's hospitals, by the total number of patient days.

      (f)

      Represents the number of visits in which patients were treated at Select Medical's outpatient rehabilitation clinics and Concentra centers during the periods presented.

      (g)

      Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated by dividing patient service revenue, excluding revenues from certain other ancillary services, by the total number of visits. For purposes of this computation for the Concentra segment, patient service revenue does not include onsite clinics and community-based outpatient clinics.

      IX. Net Income to Adjusted EBITDA Reconciliation

      For the Three and Nine Months Ended September 30, 2020 and 2021

      (In thousands, unaudited)


      The presentation of Adjusted EBITDA is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used to evaluate financial performance and determine resource allocation for each of Select Medical's operating segments. Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles ("GAAP"). Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for, net income, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying definitions, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.


      The following table reconciles net income to Adjusted EBITDA for Select Medical. Adjusted EBITDA is used by Select Medical to report its segment performance. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries.



      Three Months Ended

      September 30,


      Nine Months Ended

      September 30,


      2020


      2021


      2020


      2021

      Net income

      $

      104,457



      $

      100,217



      $

      242,391



      $

      433,639


      Income tax expense

      31,557



      27,665



      76,805



      138,410


      Interest expense

      34,026



      33,825



      117,499



      102,115


      Interest income

      —



      —



      —



      (4,749)


      Gain on sale of businesses

      (5,143)



      —



      (12,690)



      —


      Equity in earnings of unconsolidated subsidiaries

      (8,765)



      (11,452)



      (19,677)



      (33,180)


      Income from operations

      156,132



      150,255



      404,328



      636,235


      Stock compensation expense:








      Included in general and administrative

      5,600



      6,457



      16,488



      17,537


      Included in cost of services

      1,362



      1,737



      4,340



      4,465


      Depreciation and amortization

      50,110



      50,128



      154,133



      150,702


      Adjusted EBITDA

      $

      213,204



      $

      208,577



      $

      579,289



      $

      808,939










      Critical illness recovery hospital(a)

      $

      88,830



      $

      57,245



      $

      267,143



      $

      243,421


      Rehabilitation hospital

      44,637



      44,076



      110,811



      145,378


      Outpatient rehabilitation

      30,623



      38,762



      51,463



      110,724


      Concentra(b)

      80,547



      99,832



      183,510



      318,907


      Other(c)(d)

      (31,433)



      (31,338)



      (33,638)



      (9,491)


      Adjusted EBITDA

      $

      213,204



      $

      208,577



      $

      579,289



      $

      808,939



      ______________________________

      (a)

      For the nine months ended September 30, 2021, Adjusted EBITDA included other operating income of $17.9 million. The other operating income related to the outcome of litigation with the Centers for Medicare & Medicaid Services.

      (b)

      For the three and nine months ended September 30, 2021, Adjusted EBITDA included other operating income of $1.6 million and $34.0 million, respectively. For the three and nine months ended September 30, 2020, Adjusted EBITDA included other operating income of $0.4 million and $1.1 million, respectively. The other operating income is primarily related to the recognition of payments received under the Provider Relief Fund.

      (c)

      For the three and nine months ended September 30, 2021, Adjusted EBITDA included other operating income of $0.1 million and $82.0 million, respectively. For the three and nine months ended September 30, 2020, Adjusted EBITDA included a reduction to other operating income of $1.5 million and other operating income of $52.7 million, respectively. The other operating income is related to the recognition of payments received under the Provider Relief Fund.

      (d)

      Other primarily includes general and administrative costs and other operating income, as discussed further above.

      X. Reconciliation of Earnings per Common Share to Adjusted Earnings per Common Share

      For the Three and Nine Months Ended September 30, 2020 and 2021

      (In thousands, except per share amounts, unaudited)


      Adjusted net income attributable to common shares and adjusted earnings per common share are not measures of financial performance under GAAP. Items excluded from adjusted net income attributable to common shares and adjusted earnings per common share are significant components in understanding and assessing financial performance. Select Medical believes that the presentation of adjusted net income attributable to common shares and adjusted earnings per common share are important to investors because they are reflective of the financial performance of Select Medical's ongoing operations and provide better comparability of its results of operations between periods. Adjusted net income attributable to common shares and adjusted earnings per common share should not be considered in isolation or as alternatives to, or substitutes for, net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because adjusted net income attributable to common shares and adjusted earnings per common share are not measurements determined in accordance with GAAP and are thus susceptible to varying calculations, adjusted net income attributable to common shares and adjusted earnings per common share as presented may not be comparable to other similarly titled measures of other companies.


      The following tables reconcile net income attributable to common shares and earnings per common share on a fully diluted basis to adjusted net income attributable to common shares and adjusted earnings per common share on a fully diluted basis.



      Three Months Ended September 30,


      2020


      Per Share(a)


      2021


      Per Share(a)

      Net income attributable to common shares(a)

      $

      74,280



      $

      0.57



      $

      74,378



      $

      0.57


      Adjustments:(b)








      Gains on sales of businesses, net of tax effects of $234

      (1,189)



      (0.01)



      —



      —


      Adjusted net income attributable to common shares

      $

      73,091



      $

      0.56



      $

      74,378



      $

      0.57




      Nine Months Ended September 30,


      2020


      Per Share(a)


      2021


      Per Share(a)

      Net income attributable to common shares(a)

      $

      175,467



      $

      1.35



      $

      340,587



      $

      2.61


      Adjustments:(b)








      Gains on sales of businesses, net of tax effects of $3,272

      (5,089)



      (0.04)



      —



      —


      Adjusted net income attributable to common shares

      $

      170,378



      $

      1.31



      $

      340,587



      $

      2.61



      ______________________________

      (a)

      Net income attributable to common shares and earnings per common share are calculated based on the weighted average common shares outstanding, as presented in table III.

      (b)

      Adjustments to net income attributable to common shares include estimated income tax and non-controlling interest impacts and are calculated based on the diluted weighted average common shares outstanding. The estimated income tax impact, which is determined using tax rates based on the nature of the adjustment and the jurisdiction in which the adjustment occurred, includes both current and deferred income tax expense or benefit.

      XI. Net Income to Adjusted EBITDA Reconciliation

      Business Outlook for the Year Ending December 31, 2021

      (In millions, unaudited)


      The following is a reconciliation of full year 2021 Adjusted EBITDA expectations as computed at the low and high points of the range to the closest comparable GAAP financial measure. Refer to table IX for the definition of Adjusted EBITDA and a discussion of Select Medical's use of Adjusted EBITDA in evaluating financial performance. Each item presented in the below table is an estimation of full year 2021 expectations.



      Range

      Non-GAAP Measure Reconciliation

      Low


      High

      Net income attributable to Select Medical

      $

      402



      $

      417


      Net income attributable to non-controlling interests

      98



      98


      Net income

      500



      515


      Income tax expense

      162



      167


      Interest income

      (5)



      (5)


      Interest expense

      137



      137


      Equity in earnings of unconsolidated subsidiaries

      (44)



      (44)


      Income from operations

      750



      770


      Stock compensation expense

      29



      29


      Depreciation and amortization

      201



      201


      Adjusted EBITDA

      $

      980



      $

      1,000


      SOURCE Select Medical Holdings Corporation

      Modal title

      Also from this source

      Select Medical and Tallahassee Memorial HealthCare Form Joint Venture Partnership to Provide Critical Illness Recovery and Acute Care Rehabilitation Across Florida Panhandle

      Select Medical Corporation and Tallahassee Memorial HealthCare (TMH) announced today they have entered a joint venture partnership to operate a...

      Select Medical Holdings Corporation Acquired by Consortium Led by Robert A. Ortenzio, Martin F. Jackson, and WCAS

      Select Medical Holdings Corporation (the "Company" or "Select Medical," "we," "us," or "our") (NYSE: SEM) today announced the completion of its...

      More Releases From This Source

      Explore

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Dividends

      Dividends

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.